Modeling Hiv Transmission And Aids In The United States

The disease that came to be called acquired immunodeficiency syndrome (AIDS) was first identified in the summer of 1981. By that time, nearly 100,000 persons in the United States may have been infected with human immunodeficiency virus (HIV). By the time the routes of transmission were clearly identified and HIV was established as the cause of AIDS in 1983, over 300,000 people may have been infected. That number has continued to increase, with approximately 1,000,000 Americans believed to be infected in 1991. The epidemic is of great public health concern because HlV is infectious, causes severe morbidity and death in most if not all of those infected, and often occurs in relatively young persons. In addition, the cost of medical care for a person with HIV disease is high, and the medical care needs of HIV-infected persons place a severe burden on the medical care systems in many areas. Understanding and controlling the HIV epidemic is a particularly difficult challenge. The long and variable period between HIV infection and clinical disease makes it difficult both to forecast the future magnitude of the epidemic, which is important for health care planning, and to estimate the number infected in the last several years, which is important for monitoring the current status of the epidemic.

This book discusses systematically treatment on the development of stochastic, statistical and state space models of the HIV epidemic and of HIV pathogenesis in HIV-infected individuals, and presents the applications of these models. The book is unique in several ways: (1) it uses stochastic difference and differential equations to present the stochastic models of the HIV epidemic and HIV pathogenesis; in this sense, the deterministic models are considered as special cases when the numbers of different type of people or cells are very large; (2) it provides a critical analysis of deterministic and statistical models in the literature; (3) it develops state space models by combining stochastic models and statistical models; and (4) it provides a detailed discussion on the pros and cons of the different modeling approaches. This book is the first to introduce state space models for the HIV epidemic. It is also the first to develop stochastic models and state space models for the HIV pathogenesis in HIV-infected individuals.

This book presents models describing HIV transmission rates at population level, discussing the main statistical methods and analytical interventions. It also assesses the practical applicability of the various modelling techniques, offering readers insights into what methods are available and, more importantly, when they should be used to address HIV transmission at global level. The book includes realistic simulation models fitted to clarify the rate of HIV mother-to-child transmission (HIV MTCT), and substantiates the conclusions that can be drawn as well as the appropriate time for making global-level clinical decisions concerning people living with HIV/AIDS (PLHIVs). Intended for students, academics and researchers, the book offers more than just an introduction to the topic – it also features in-depth, yet easy-to-understand, descriptions of a new mathematical/statistical HIV mother-to-child transmission model, making it a useful resource for clinicians, public health workers and policymakers involved in implementing HIV-prevention programmes at national /global level.

Infectious diseases are the leading cause of death globally, particularly among children and young adults. The spread of new pathogens and the threat of antimicrobial resistance pose particular challenges in combating these diseases. Major Infectious Diseases identifies feasible, cost-effective packages of interventions and strategies across delivery platforms to prevent and treat HIV/AIDS, other sexually transmitted infections, tuberculosis, malaria, adult febrile illness, viral hepatitis, and neglected tropical diseases. The volume emphasizes the need to effectively address emerging antimicrobial resistance, strengthen health systems, and increase access to care. The attainable goals are to reduce incidence, develop innovative approaches, and optimize existing tools in resource-constrained settings.

- Only book on extensive, deterministic models, statistic models, stochastic models and state space models and statistical methods for HIV epidemic involving IV drug usage and HIV epidemic in homosexual populations. - Provides most recent biological insights into HIV pathogenesis and HIV kinetics at the cellular level, and illustrates how to build up mathematical models based on these biological insights. - Only publication that provides in-depth analysis of HAART treatment protocols and discusses possible improvements to the HAART protocol. The book also provides connection between pharmacokinetics with treatment in HIV-infected individuals.

During the early years of the AIDS epidemic, thousands of Americans became infected with HIV through the nation's blood supply. Because little reliable information existed at the time AIDS first began showing up in hemophiliacs and in others who had received transfusions, experts disagreed about whether blood and blood products could transmit the disease. During this period of great uncertainty, decision-making regarding the blood supply became increasingly difficult and fraught with risk. This volume provides a balanced inquiry into the blood safety controversy, which involves private sexual practices, personal tragedy for the victims of HIV/AIDS, and public confidence in America's blood services system. The book focuses on critical decisions as information about the danger to the blood supply emerged. The committee draws conclusions about what was doneâ€"and recommends what should be done to produce better outcomes in the face of future threats to blood safety. The committee frames its analysis around four critical area: Product treatmentâ€"Could effective methods for inactivating HIV in blood have been introduced sooner? Donor screening and referralâ€"including a review of screening to exlude high-risk individuals. Regulations and recall of contaminated bloodâ€"analyzing decisions by federal agencies and the private sector. Risk communicationâ€"examining whether infections could have been averted by better communication of the risks.